Ligand Pharmaceuticals VP Charles S. Berkman Sells 7,166 Shares (LGND)
Ligand Pharmaceuticals (NASDAQ:LGND) VP Charles S. Berkman sold 7,166 shares of Ligand Pharmaceuticals stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $66.90, for a total transaction of $479,405.40. Following the completion of the sale, the vice president now directly owns 26,978 shares of the company’s stock, valued at approximately $1,804,828. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of Ligand Pharmaceuticals (NASDAQ:LGND) traded down 0.36% on Wednesday, hitting $66.86. The stock had a trading volume of 157,529 shares. Ligand Pharmaceuticals has a 1-year low of $28.19 and a 1-year high of $80.42. The stock has a 50-day moving average of $64.58 and a 200-day moving average of $62.73. The company has a market cap of $1.386 billion and a P/E ratio of 115.09.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its earnings data on Wednesday, May 7th. The company reported $0.35 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.25 by $0.10. The company had revenue of $16.00 million for the quarter, compared to the consensus estimate of $13.63 million. Ligand Pharmaceuticals’s revenue was up 36.8% compared to the same quarter last year. Analysts expect that Ligand Pharmaceuticals will post $1.44 EPS for the current fiscal year.
LGND has been the subject of a number of recent research reports. Analysts at Ned Davis Research upgraded shares of Ligand Pharmaceuticals from a “sell” rating to a “neutral” rating in a research note on Monday, April 28th. Analysts at Brinson Patrick initiated coverage on shares of Ligand Pharmaceuticals in a research note on Monday, March 24th. They set an “outperform” rating on the stock. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $70.74.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is a biotechnology company that operates with a business model focused on developing or acquiring assets.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.